Jagsonpal Pharma Q1 FY27: Revenue up 9% to ₹82.2 Cr, PAT up 22% to ₹13.2 Cr
Jagsonpal Pharmaceuticals reported Q1 FY27 results with revenue up 9% YoY to ₹82.2 Cr and PAT up 22% YoY to ₹13.2 Cr. Operating EBITDA increased 21% to ₹19.1 Cr. The company completed an 85% acquisition of Aequitas Healthcare for ₹20.8 Cr, marking entry into the hospital business. Cash reserves remain strong at ₹170 Cr.
The announcement includes strong financial performance metrics and a significant strategic acquisition, which is expected to have a substantial impact on the company's future growth and market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with a robust cash balance. The successful acquisition of Aequitas Healthcare is viewed as a strategic positive for future growth.
Jagsonpal Pharmaceuticals Limited announced its unaudited financial results for the quarter ended June 30, 2026, reporting a strong start to FY27. The company's revenue increased by 9% year-on-year to ₹822 million (₹82.2 crore), and Profit After Tax (PAT) grew by 22% year-on-year to ₹132 million (₹13.2 crore). Operating EBITDA also saw a significant rise of 21% year-on-year to ₹191 million (₹19.1 crore), with EBITDA margins expanding by 241 basis points to 23.2%.
The company maintained robust liquidity, with cash reserves at ₹1,700 million (₹170 crore) despite completing a ₹400 million (₹40 crore) share buyback. This financial strength has supported the strategic acquisition of an 85% stake in Aequitas Healthcare for ₹208 million (₹20.8 crore) in an all-cash deal. This acquisition marks Jagsonpal's foray into the hospital business segment, with Aequitas generating a revenue of ₹533 million (₹53.3 crore) in FY26 and targeting over ₹100 million (₹10 crore) in EBITDA within two years post-integration.
Manish Gupta, Managing Director and CEO, highlighted the company's sustained traction and outperformance against the industry benchmark. He emphasized the strategic importance of the Aequitas acquisition and the share buyback, both contributing to improved ROCE by 340 basis points. Jagsonpal Pharmaceuticals Limited aims to sustain profitable growth through its strong business franchise, disciplined capital allocation, and pursuit of value-accretive inorganic opportunities.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.